Literature DB >> 27647310

Upregulation of Aβ42 in the Brain and Bodily Fluids of Rhesus Monkeys with Aging.

Qiao Zhao1,2, Jing Lu1,2, Zitong Yao1,2, Shubo Wang1,2, Liming Zhu1,2, Ju Wang1,2, Baian Chen3,4.   

Abstract

The cerebral accumulation of amyloid beta (Aβ) is one of the key pathological hallmarks of Alzheimer's disease (AD). Aβ is also found in bodily fluids such as the cerebrospinal fluid (CSF) and plasma. However, the significance of Aβ accumulation in the brain and different bodily pools, as well as its correlation with aging and cerebral amyloid pathology, is not completely understood. To better understand this question, we selected the rhesus monkey, which is phylogenetically and physiologically highly similar to the human, as a model to study. We quantified the levels of the two main Aβ isoforms (Aβ42 and Aβ40) in different sections of the brain (frontal cortex, temporal cortex, and hippocampus) and bodily fluids (CSF and plasma) of rhesus monkeys at different developmental phases (young, 5-9 years of age; mature, 10-19 years of age; and old, 21-24 years of age). We found that the levels of neuronal and insoluble Aβ42 increased significantly in the brain with aging, suggesting that this specific isoform might be directly involved in aging and AD-like pathophysiology. There was no significant change in the Aβ40 level in the brain with aging. In addition, the Aβ42 level, but not the Aβ40 level, in both the CSF and plasma increased with aging. We also identified a positive correlation between Aβ42 in the CSF and plasma and Aβ42 in the brain. Taken collectively, our results indicate that there is an association between Aβ accumulation and age. These results support the increased incidence of AD with aging.

Entities:  

Keywords:  Aging; Alzheimer’s disease; Amyloid beta peptide; Bodily fluids; Rhesus monkeys

Mesh:

Substances:

Year:  2016        PMID: 27647310     DOI: 10.1007/s12031-016-0840-6

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  23 in total

1.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

Review 2.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 3.  A review on Alzheimer's disease pathophysiology and its management: an update.

Authors:  Anil Kumar; Arti Singh
Journal:  Pharmacol Rep       Date:  2014-09-22       Impact factor: 3.024

Review 4.  Alzheimer's disease and amyloid: culprit or coincidence?

Authors:  Stephen D Skaper
Journal:  Int Rev Neurobiol       Date:  2012       Impact factor: 3.230

Review 5.  Amyloid precursor protein processing and Alzheimer's disease.

Authors:  Richard J O'Brien; Philip C Wong
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

6.  2015 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2015-03       Impact factor: 21.566

Review 7.  Animal models of Alzheimer's disease: therapeutic implications.

Authors:  Diana S Woodruff-Pak
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease.

Authors:  Rebecca F Rosen; Lary C Walker; Harry Levine
Journal:  Neurobiol Aging       Date:  2009-03-28       Impact factor: 4.673

9.  Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease.

Authors:  E Hellström-Lindahl; M Viitanen; A Marutle
Journal:  Neurochem Int       Date:  2009-03-20       Impact factor: 3.921

10.  Loss of presenilin function is associated with a selective gain of APP function.

Authors:  Carole Deyts; Mary Clutter; Stacy Herrera; Natalia Jovanovic; Anna Goddi; Angèle T Parent
Journal:  Elife       Date:  2016-05-19       Impact factor: 8.140

View more
  5 in total

1.  The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys.

Authors:  Susan E Boehnke; Emma L Robertson; Brittney Armitage-Brown; Robert G Wither; Natalia M Lyra E Silva; Andrew Winterborn; Ron Levy; Douglas J Cook; Fernanda G De Felice; Douglas P Munoz
Journal:  Alzheimers Dement (Amst)       Date:  2020-07-13

2.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01

3.  Brains of rhesus monkeys display Aβ deposits and glial pathology while lacking Aβ dimers and other Alzheimer's pathologies.

Authors:  Jing Zhang; Baian Chen; Jing Lu; Yi Wu; Shubo Wang; Zitong Yao; Liming Zhu; Yanhua Qiao; Quan Sun; Wei Qin; Qiao Zhao; Jianping Jia; Cuibai Wei
Journal:  Aging Cell       Date:  2019-06-04       Impact factor: 9.304

4.  Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys.

Authors:  Emma L Robertson; Susan E Boehnke; Natalia de M Lyra E Silva; Brittney Armitage-Brown; Andrew Winterborn; Douglas J Cook; Fernanda G De Felice; Douglas P Munoz
Journal:  Alzheimers Dement (N Y)       Date:  2022-04-05

5.  Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults.

Authors:  Ge Li; Jane B Shofer; Eric C Petrie; Chang-En Yu; Charles W Wilkinson; Dianne P Figlewicz; Andrew Shutes-David; Jing Zhang; Thomas J Montine; Murray A Raskind; Joseph F Quinn; Douglas R Galasko; Elaine R Peskind
Journal:  Alzheimers Res Ther       Date:  2017-07-03       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.